...
首页> 外文期刊>American Family Physician >Warfarin therapy: evolving strategies in anticoagulation.
【24h】

Warfarin therapy: evolving strategies in anticoagulation.

机译:华法林疗法:抗凝治疗的发展策略。

获取原文
获取原文并翻译 | 示例

摘要

Warfarin is the oral anticoagulant most frequently used to control and prevent thromboembolic disorders. Prescribing the dose that both avoids hemorrhagic complications and achieves sufficient suppression of thrombosis requires a thorough understanding of the drug's unique pharmacology. Warfarin has a complex dose-response relationship that makes safe and effective use a challenge. For most indications, the dose is adjusted to maintain the patient's International Normalized Ratio (INR) at 2 to 3. Because of the delay in factor II (prothrombin) suppression, heparin is administered concurrently for four to five days to prevent thrombus propagation. Loading doses of warfarin are not warranted and may result in bleeding complications. Interactions with other drugs must be considered, and therapy in elderly patients requires careful management. Current dosing recommendations are reviewed, and practical guidelines for the optimal use of warfarin are provided.
机译:华法林是最常用于控制和预防血栓栓塞性疾病的口服抗凝剂。既要避免出血并发症,又要充分抑制血栓形成的剂量,需要对药物独特的药理学有透彻的了解。华法林具有复杂的剂量反应关系,这使安全有效地使用成为一个挑战。对于大多数适应症,应调整剂量以将患者的国际标准化比率(INR)维持在2至3。由于II型因子(凝血酶原)抑制作用的延迟,因此肝素同时给药4至5天以防止血栓扩散。不保证服用华法林剂量,并可能导致出血并发症。必须考虑与其他药物的相互作用,老年患者的治疗需要仔细的管理。审查了当前的剂量建议,并提供了最佳使用华法林的实用指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号